Wirestock/iStock Editorial via Getty Images
GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration.
Under the agreement signed by both companies, GSK (GSK) will pay $1 billion upfront, with the potential for an additional $150 million success-based